University of Natural Resources and Life Sciences, Vienna

Andrea Schenker-Wicki, President of the University of Basel, Switzerland’s oldest university and a leading global research university, will be honored by AUW on April 5

Retrieved on: 
Saturday, April 15, 2023
University of Zurich, University of Basel, National Agricultural Research, Extension, Education, and Economics Advisory Board, University, Radioactive decay, Education, National Science Board, Roche, ETH Zurich, BANGLADESH, Research, Doctor of Philosophy, Advisory board, Economics, Business administration, Student, AUW, Islam, Trustee, Natural Resources, University of Natural Resources and Life Sciences, Vienna, Law, University of Fribourg, Quality assurance, Jatiya Sangsad, Female, Medical device, Nursing, Management, Basel, Chemistry, Accreditation, Woman

Bangladesh's Information Minister Hon'ble Dr. Hasan Mahmud (who earned his PhD in Chemistry from Belgium) will speak as the Chief Guest in honoring Professor Schenker-Wicki.

Key Points: 
  • Bangladesh's Information Minister Hon'ble Dr. Hasan Mahmud (who earned his PhD in Chemistry from Belgium) will speak as the Chief Guest in honoring Professor Schenker-Wicki.
  • The AUW Choir will perform the national anthems of both Bangladesh and Switzerland to mark this special occasion.
  • "You are all welcome to Bangladesh," the Prime Minister said to the five Afghan women from AUW who met with her.
  • She is the recipient of an honorary doctorate from the University of Natural Resources and Life Sciences in Vienna.

Utility Selects US-Based Hydropower Innovator Natel Energy to Expand Hydro’s Reach in Austria

Retrieved on: 
Wednesday, December 21, 2022
Natel Energy, Partnership, BOKU, RHT, Trout, Mur (river), University of Natural Resources and Life Sciences, Vienna, Salmon, Democratic republic, Growth, Natural Resources, River, Symbion Power, University, Congo, Climate change, Biodiversity, Ecology, Environment, Renewable energy, Sauerbrunn, EU, Natel

Alameda, California, Dec. 21, 2022 (GLOBE NEWSWIRE) -- In partnership with leading Austrian utility company, Energie Steiermark, Natel Energy has just commissioned its first European hydropower project.

Key Points: 
  • Alameda, California, Dec. 21, 2022 (GLOBE NEWSWIRE) -- In partnership with leading Austrian utility company, Energie Steiermark, Natel Energy has just commissioned its first European hydropower project.
  • “Austria, like the rest of Europe, is working hard to swiftly shift its energy sources to a greater number of renewable providers.
  • The Sauerbrunn Hydro Project marks the third active project for Natel Energy and the springboard for Natel’s continued growth in Europe.
  • Natel is expediting the energy transition with modern, sustainable hydropower that supports healthy rivers, and with accurate, timely decision-making tools that improve water resource management.

Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program

Retrieved on: 
Tuesday, August 23, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Enzyme, University, Security (finance), Breast, Metastasis, Cancer, Program, Research, POP1, Liver, Brain, Protein, Budget, Kidney, PRP, Chymotrypsinogen, Recurrence, Trypsinogen, Science, Lung, Securities and Exchange Commission (Philippines), PPCB, Accounting, List of life sciences, Animal, Refrigeration, Pancreas, Natural Resources, Company, FDA, B cell, Prostate, Institute, University of Natural Resources and Life Sciences, Vienna, Growth, OTCQB, Patient, Pharmaceutical industry, Medical imaging, Microbiology

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that recombinant trypsinogen and chmyotrypsinogen were synthesized via the Proenzyme Optimization Project (POP1) joint research and drug discovery program.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that recombinant trypsinogen and chmyotrypsinogen were synthesized via the Proenzyme Optimization Project (POP1) joint research and drug discovery program.
  • According to Emergen Research, the global metastatic cancer market is projected to be worth $111 Billion by 2027.
  • The objective of the POP1 program is to produce large quantities of trypsinogen and chymotrypsinogen for commercial use that exhibits minimal variation between lots and without sourcing the proenzymes from animals.
  • PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection.

Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program

Retrieved on: 
Tuesday, July 19, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Research, University, Lung, Recurrence, OTCQB, B cell, Patient, Cancer, PRP, Security (finance), U.S. Securities and Exchange Commission, Prostate, Science, Program, Natural Resources, Brain, Budget, Accounting, Chymotrypsinogen, Diabetes, Animal, Kidney, Metastasis, Liver, Company, List of life sciences, Eli Lilly, Bachelor of Medicine, Bachelor of Surgery, Insulin, Growth, Pancreas, Enzyme, PPCB, MD, Breast, MB, FDA, Trypsinogen, University of Natural Resources and Life Sciences, Vienna, POP1, Institute, Pharmaceutical industry, Medical imaging, Microbiology

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that successful production of a synthetic recombinant version of the proenzyme trypsinogen was completed via the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that successful production of a synthetic recombinant version of the proenzyme trypsinogen was completed via the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program.
  • The programs lead research scientist, Mr. Aitor Gonzlez, was able to produce the recombinant trypsinogen successfully.
  • Previously, attempts to produce synthetic trypsinogen when manufacturing in larger quantities were unable to be stabilized.
  • This process will also be repeated for recombinant chymotrypsinogen to manufacture a synthetic recombinant formulation to the Companys lead product candidate, PRP.

Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs

Retrieved on: 
Tuesday, January 4, 2022
Clinical trial, AVCO, COVID-19, University, RNA transfection, Acquisition, Therapy, Regenerative medicine, Growth, Research, Company, Forward-looking statement, Patient, University of Pittsburgh Medical Center, IND, Cancer, Public policy, U.S. Securities and Exchange Commission, BOKU, Security (finance), List of life sciences, NASDAQ, Exosome, Natural Resources, Partnership, Patent, UPMC, GLOBE, Technology, CAR, Celltech, Cell membrane, University of Natural Resources and Life Sciences, Vienna, R, Pharmaceutical industry, Vaccine

FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update.

Key Points: 
  • FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update.
  • We believe we have made significant progress in 2021, advancing our scientific and clinical programs focusing on immuno-oncology and cellular medicines, said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.
  • We have partnered with world-renowned research centers and universities on cutting edge research, and are accelerating our own innovative research, bio-process development, clinical programs and product commercialization.
  • Avalon is on track to initiate AVA-011 first-in-human clinical trial by mid-2022.

Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy

Retrieved on: 
Thursday, October 14, 2021
Natural Resources, Exosome, Technology, University of Natural Resources and Life Sciences, Vienna, Program, PCT, Growth, RNA transfection, Public policy, Security (finance), GPS, Therapy, USPTO, BOKU, RNA, DNA, Solubility, GLOBE, U.S. Securities and Exchange Commission, Forward-looking statement, Company, University, List of life sciences, AVCO, Nano, Patent, NASDAQ, Celltech, COVID-19, Pharmaceutical industry, Vaccine

Avalon and Professor Uwe Sleytr of BOKU have jointly filed USPTO (US63/060,235) and international PCT (US21/38327) patent applications pertaining to the novel SLET platform.

Key Points: 
  • Avalon and Professor Uwe Sleytr of BOKU have jointly filed USPTO (US63/060,235) and international PCT (US21/38327) patent applications pertaining to the novel SLET platform.
  • This emulsome nano-carrier, when loaded with bio-active agents (such as poorly water-soluble pharmaceuticals and genetic materials, including DNA and RNA), may increase their solubility and bioavailability.
  • Avalon is actively exploring the practical uses of SLET, including targeted drug delivery, vaccine development, diagnostic devices, and cellular therapeutic applications.
  • The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy.

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases

Retrieved on: 
Thursday, October 7, 2021
NASDAQ, Company, Forward-looking statement, Biology, University of Natural Resources and Life Sciences, Vienna, Department, Celltech, COVID-19, King Abdulaziz University, University, Cell, Biochemistry, List of life sciences, KTH Royal Institute of Technology, GLOBE, Growth, Cancer, Science for Life Laboratory, Natural Resources, Division, U.S. Securities and Exchange Commission, Institute, Communication, Public policy, Security (finance), Cell-free system, AVCO, Knowledge, Exosome, Therapy, Membrane protein, Partnership, Department of Biochemistry, University of Oxford, BOKU, Science, Tissue, Fine chemical, Pharmaceutical industry, Vaccine

The new technology reveals that difficult-to-study cell membrane proteins can be efficiently expressed in a cell-free system, allowing for their evaluation as potentially druggable targets.

Key Points: 
  • The new technology reveals that difficult-to-study cell membrane proteins can be efficiently expressed in a cell-free system, allowing for their evaluation as potentially druggable targets.
  • Proteins function within cells and are also present on cell surfaces, embedded within the cells outer membrane.
  • These membrane proteins include cell surface receptors that function in cell signaling and regulation of communication with other cells and tissues.
  • These molecules are important drug targets and include receptors on immune cells such as T-cells for the development of cellular immunotherapies.

Juniper Research Recognizes Boku with two ‘Future Digital Awards’

Retrieved on: 
Thursday, October 1, 2020
Money, Payment systems, Boku, Finance, Digital wallet, University of Natural Resources and Life Sciences, Vienna, Economy, Mobile payments

The Future Digital Awards are organized by Juniper Research to recognize companies which have made outstanding contributions to their industry and are likely to make a significant impact in the future.

Key Points: 
  • The Future Digital Awards are organized by Juniper Research to recognize companies which have made outstanding contributions to their industry and are likely to make a significant impact in the future.
  • The two awards recognize the unique value that Boku delivers to both mobile payments and identity on a global basis.
  • The Best Mobile Money Offering award winner comes after Boku has integrated and launched several mobile wallets into its global payments network.
  • Jon Prideaux, CEO Boku, commented, Boku are thrilled to be recognized in both focus areas of our business.